investorscraft@gmail.com

Stock Analysis & ValuationCullinan Therapeutics, Inc. (CGEM)

Previous Close
$15.74
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

One Main Street
Cambridge, MA 02142
United States
Phone: 617 410 4650
Industry: Medical - Pharmaceuticals
Sector: Healthcare
CEO: Nadim Ahmed
Full Time Employees: 111

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

HomeMenuAccount